Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow 89bio, Inc.

Get SEC filing alerts via email and in your feed for 89bio, Inc.

ETNB

89bio, Inc.

About 89bio, Inc.

89bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for liver and cardio-metabolic diseases. Its lead product, pegozafermin, targets metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). With significant market potential driven by rising obesity rates, 89bio aims to address unmet medical needs through ongoing clinical trials and has received Breakthrough Therapy designation from the FDA, enhancing its growth prospects.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from 89bio, Inc.

1
1
89bio, Inc. 89bio Reports $111.5 Million Net Loss in Q2 2025, Driven by Increased R&D Expenses

Via official filing (AI summary) | 11 months ago | 0 comments

2
1
89bio, Inc. 89bio Reports $71.3 Million Net Loss and $315.4 Million Cash Position in Latest 10-Q

Via official filing (AI summary) | about 1 year ago | 0 comments

3
1
89bio, Inc. 89bio Reports $367.1 Million Net Loss and Advances Pegozafermin Development

Via official filing (AI summary) | over 1 year ago | 0 comments

4
1
89bio, Inc. 89bio Reports Significant Financial Decline, Increased Expenses, and Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments